Unusual Machines (UMAC) Director Receives 2,308 Restricted Shares
Rhea-AI Filing Summary
Insider grant and resulting holdings: Director Jeffrey M. Thompson received a grant of 2,308 shares of restricted common stock of Unusual Machines, Inc. (UMAC) on 08/19/2025. The shares were granted under the issuer's 2022 Equity Incentive Plan, are fully vested, and are subject to the company’s standard Restricted Stock Agreement. The grant was approved by the Board and exempt from Section 16(b) under Rule 16b-3. Following the grant, Thompson beneficially owns 337,460 shares. The Form 4 was signed on 08/21/2025.
Positive
- Board-approved grant of restricted common stock, indicating formal corporate governance procedures were followed
- Rule 16b-3 exemption applied, meaning the grant is exempt from short-swing profit recovery requirements
- Shares are fully vested at grant and documented under the issuer's 2022 Equity Incentive Plan
Negative
- None.
Insights
TL;DR: Director received 2,308 vested restricted shares; ownership now 337,460 shares, a routine Board-approved equity grant.
The Form 4 documents a board-approved equity award to Director Jeffrey M. Thompson consisting of 2,308 restricted common shares granted on 08/19/2025 at $0, reflecting a compensation or retention-related issuance rather than an open-market purchase or sale. The grant was processed under the 2022 Equity Incentive Plan and exempt from short-swing liability via Rule 16b-3. For investors, this is a disclosed insider compensation event that increases Thompson's beneficial stake to 337,460 shares; it does not, by itself, disclose any change in trading activity or company performance metrics.
TL;DR: Governance process followed: Board approval, Rule 16b-3 exemption, and standard restricted stock agreement applied.
The filing clearly states the grant was approved by the issuer's Board and granted under the company’s equity plan, satisfying Rule 16b-3 conditions that exempt the award from Section 16(b) clawback for short-swing profits. The shares are fully vested but subject to the issuer’s Restricted Stock Agreement, indicating standard post-grant contractual terms. This appears to be a routine director compensation action with proper disclosure and signature on 08/21/2025.